Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:CORTNASDAQ:ROIVNASDAQ:TRIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$39.16-1.2%$35.10$21.62▼$40.40$7.43B1.12.48 million shs1.52 million shsCORTCorcept Therapeutics$70.34-1.2%$71.49$28.04▼$117.33$7.46B0.191.15 million shs405,585 shsROIVRoivant Sciences$11.29-1.6%$10.76$8.73▼$13.06$7.67B1.165.57 million shs4.05 million shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+1.54%+3.42%+19.21%+20.26%+38.25%CORTCorcept Therapeutics-0.08%+3.14%+0.84%+27.08%+118.08%ROIVRoivant Sciences+1.68%+2.41%+6.60%+7.60%+5.91%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.5561 of 5 stars4.52.00.03.92.13.30.6CORTCorcept Therapeutics4.5917 of 5 stars3.51.00.04.22.74.21.9ROIVRoivant Sciences2.3766 of 5 stars3.53.00.00.01.92.50.0TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$57.3646.49% UpsideCORTCorcept Therapeutics 3.00Buy$138.2596.55% UpsideROIVRoivant Sciences 3.00Buy$17.5054.98% UpsideTRILTrillium Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRIL, ROIV, CORT, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $56.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/30/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.004/30/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.004/30/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $72.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $53.004/3/2025CORTCorcept TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.004/1/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $142.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$127.42M58.36N/AN/A($7.71) per share-5.08CORTCorcept Therapeutics$685.45M10.88$1.03 per share67.96$4.92 per share14.30ROIVRoivant Sciences$29.05M264.22N/AN/A$7.76 per share1.46TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%7/30/2025 (Estimated)CORTCorcept Therapeutics$106.14M$1.1655.8438.02N/A22.35%24.54%20.24%8/4/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.25N/AN/AN/A-119.54%-14.05%-12.81%8/6/2025 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ALatest TRIL, ROIV, CORT, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67CORTCorcept Therapeutics0.013.703.64ROIVRoivant SciencesN/A37.9137.91TRILTrillium TherapeuticsN/A19.8219.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%CORTCorcept Therapeutics93.61%ROIVRoivant Sciences64.76%TRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%CORTCorcept Therapeutics20.80%ROIVRoivant Sciences7.90%TRILTrillium Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableCORTCorcept Therapeutics300106.05 million83.30 millionOptionableROIVRoivant Sciences860679.81 million657.18 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRIL, ROIV, CORT, and BBIO HeadlinesRecent News About These CompaniesTrillium Therapeutics Stock Price HistoryMay 26, 2025 | investing.comTTI Consumer Power Tools, Inc. is Seeking an IP ParalegalSeptember 26, 2024 | ipwatchdog.comAdvances in Drug Discovery & Development 2024September 8, 2024 | technologynetworks.comWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comGoogle Cloud unveils the Trillium TPU, its most powerful AI processor so farMay 14, 2024 | siliconangle.comCachet Bicycle shakes off COVIDFebruary 25, 2024 | baytoday.caRejuvenate your look with a trip to Fourth Avenue Medical AestheticsJanuary 30, 2024 | chch.comTTI apprehends motorists for illegal removal of clamps, hunt for four others underwayJanuary 30, 2024 | bulawayo24.comBridgeBio raises $1.25bn, and other biotech financingsJanuary 19, 2024 | pharmaphorum.comRatio Therapeutics Raises $50M in Series B FinancingJanuary 17, 2024 | precisionmedicineonline.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comRatio Therapeutics unveils new research and development facilityMay 15, 2023 | biopharma-reporter.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comTrillium House, an affordable housing project in Warrenton, close to completionJanuary 10, 2023 | dailyastorian.comFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaOctober 19, 2022 | nz.finance.yahoo.comCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeptember 14, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsRenaissance Hedge Fund’s Biggest Q1 Buys RevealedBy Leo Miller | May 22, 2025View Renaissance Hedge Fund’s Biggest Q1 Buys RevealedTRIL, ROIV, CORT, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$39.16 -0.49 (-1.24%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Corcept Therapeutics NASDAQ:CORT$70.34 -0.84 (-1.18%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Roivant Sciences NASDAQ:ROIV$11.29 -0.18 (-1.55%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Trillium Therapeutics NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
